{"article_title": "Exithera raising $9M, develops pill as next-gen anti-stroke medication", "article_keywords": ["raised", "medication", "9m", "filings", "series", "million", "nextgen", "antistroke", "round", "access", "develops", "westborough", "exithera", "cbi", "pill", "raising", "hayward"], "article_url": "http://medcitynews.com/2014/08/exithera-raising-9m-develops-pill-develop-next-gen-anti-stroke-med/", "article_text": "Exithera Pharmaceuticals, a player in the anti-thrombosis and stroke prevention drug space, appears to be in the midst of a $9 million Series B round, according to regulatory filings. It has raised $3 million thus far, the filings said.\n\nLast we heard, the Westborough, Massachusetts company raised $2 million of a $4 million Series A round in August 2012; president and CEO Neil Hayward told Mass High Tech that the funding came from Access BridgeGap Ventures, the now-defunct venture arm of Access Industries. Its major investor now \u2013 owning 65 percent of Exithera \u2013 is Israel investment group CBI, which is owned by Access Industries.\n\nWe\u2019re sort of grasping at straws here until Hayward calls us back \u2013 but here\u2019s a nice little precis of what the company\u2019s up to, courtesy of CBI:", "article_metadata": {"description": "Exithera Pharmaceuticals, a player in the anti-thrombosis and stroke prevention drug space, appears to be in the midst of a $9 million Series B round, according to regulatory filings. It has raised $3 million thus far, the filings said. Last we heard, the Westborough, Massachusetts company raised $2 million of a $4 million Series A round in August 2012; president and CEO Neil Hayward told Mass High Tech that the funding came from Access BridgeGap Ventures, the now-defunct venture arm of Access Industries. Its major investor now \u2013 owning 65 percent of Exithera \u2013 is Israel investment group\u00a0CBI, which is owned by\u00a0Access Industries. We\u2019re sort of grasping at straws here until Hayward calls us back \u2013 but here\u2019s a nice little precis of what the company\u2019s up to, courtesy of CBI: eXIthera Pharmaceuticals stroke prevention and antithrombosis drugs are based on the unique pathophysiological role of Factor XI in the initiation of intravascular thrombi without causing undue bleeding. Thrombosis prevention without bleeding has been demonstrated unequivocally in numerous animal studies. Most exciting is the dramatic reduction in the incidence of ischemic stroke in Factor XI deficient individuals. In addition, these patients present little or no bleeding liabilities in spite of their deficiency. eXIthera\u2019s drug candidates are small, orally active, and highly selective Factor XI inhibitors. eXIthera believes that these drugs will be highly effective in stroke and thrombosis prevention without the bleeding liabilities of current anticoagulants.", "generator": "WordPress 4.5.2", "og": {"site_name": "MedCity News", "description": "Exithera Pharmaceuticals, a player in the anti-thrombosis and stroke prevention drug space, appears to be in the midst of a $9 million Series B round, according to regulatory filings. It has raised $3 million thus far, the filings said. Last we heard, the Westborough, Massachusetts company raised $2 million of a $4 million Series A round in August 2012; president and CEO Neil Hayward told Mass High Tech that the funding came from Access BridgeGap Ventures, the now-defunct venture arm of Access Industries. Its major investor now \u2013 owning 65 percent of Exithera \u2013 is Israel investment group\u00a0CBI, which is owned by\u00a0Access Industries. We\u2019re sort of grasping at straws here until Hayward calls us back \u2013 but here\u2019s a nice little precis of what the company\u2019s up to, courtesy of CBI: eXIthera Pharmaceuticals stroke prevention and antithrombosis drugs are based on the unique pathophysiological role of Factor XI in the initiation of intravascular thrombi without causing undue bleeding. Thrombosis prevention without bleeding has been demonstrated unequivocally in numerous animal studies. Most exciting is the dramatic reduction in the incidence of ischemic stroke in Factor XI deficient individuals. In addition, these patients present little or no bleeding liabilities in spite of their deficiency. eXIthera\u2019s drug candidates are small, orally active, and highly selective Factor XI inhibitors. eXIthera believes that these drugs will be highly effective in stroke and thrombosis prevention without the bleeding liabilities of current anticoagulants.", "title": "Exithera raising $9M, develops pill as next-gen anti-stroke medication", "locale": "en_US", "image": "http://medcitynews.com/wp-content/uploads/dollarbills-1024x793.jpg", "updated_time": "2014-09-07T23:02:18-04:00", "url": "http://medcitynews.com/2014/08/exithera-raising-9m-develops-pill-develop-next-gen-anti-stroke-med/", "type": "article"}, "twitter": {"image": "http://medcitynews.com/wp-content/uploads/dollarbills-1024x793.jpg", "creator": "@meghanakeshavan", "description": "Exithera Pharmaceuticals, a player in the anti-thrombosis and stroke prevention drug space, appears to be in the midst of a $9 million Series B round, according to regulatory filings. It has raised $3 million thus far, the filings said. Last we heard, the Westborough, Massachusetts company raised $2 million of a $4 million Series A round in August 2012; president and CEO Neil Hayward told Mass High Tech that the funding came from Access BridgeGap Ventures, the now-defunct venture arm of Access Industries. Its major investor now \u2013 owning 65 percent of Exithera \u2013 is Israel investment group\u00a0CBI, which is owned by\u00a0Access Industries. We\u2019re sort of grasping at straws here until Hayward calls us back \u2013 but here\u2019s a nice little precis of what the company\u2019s up to, courtesy of CBI: eXIthera Pharmaceuticals stroke prevention and antithrombosis drugs are based on the unique pathophysiological role of Factor XI in the initiation of intravascular thrombi without causing undue bleeding. Thrombosis prevention without bleeding has been demonstrated unequivocally in numerous animal studies. Most exciting is the dramatic reduction in the incidence of ischemic stroke in Factor XI deficient individuals. In addition, these patients present little or no bleeding liabilities in spite of their deficiency. eXIthera\u2019s drug candidates are small, orally active, and highly selective Factor XI inhibitors. eXIthera believes that these drugs will be highly effective in stroke and thrombosis prevention without the bleeding liabilities of current anticoagulants.", "card": "summary", "title": "Exithera raising $9M, develops pill as next-gen anti-stroke medication - MedCity News"}, "robots": "noodp", "fb": {"app_id": 148725768475669}, "google-site-verification": "xudQg7nxVR9ifmMTY4Tf-0wVtX9b6rWLQd0utCweGOc", "keywords": "weight loss, obesity, overweight,diabetes,massachusetts,medical devices,obesity,startups,healthcare innovation, medcity news,medcity news,san francisco, startups, life sciences,accelerator,rock health,startup advice,startup funding,patient monitoring system, motion sensors ,dc,healthcare it,washington,foodborne pathogens, diagnostics company, diagnostic platforms,minimally invasive surgery, laser surgery,cambridge,dealflow,hospitals,wellpoint, healthways, health and wellness, employee wellness programs,investing,wellness,medtronic, shanghai innovation center, china, r&d,china,mdt,minneapolis,minnesota,publics,twin cities,ulcerative colitis, abbott labs, humira,abbott labs,doctors,pharmaceuticals,skin disorders, pharmaceuticals, md anderson cancer center,cancer,texas,renal denervation, st. jude medical,st. jude medical,stj,emr, ehr, electronic health records, electronic medical records, certified emr,certified emr,ehr,electronic health records,electronic medical records,advanced cellular technology,amyotrophic lateral sclerosis,embryonic stem cells,geron corporation,lou gehrig\\'s disease,macular degeneration,regenerative medicine,spinal cord damage,value-based healthcare system, obamacare, fee-for-service model,california,cleveland,health insurance,insurance,ohio,pennsylvania,politics,cancer treatment options library, aetna, aet, healthcare it,aet,aetna,health it,phi,philadelphia,anticoagulent, Boston, exithera, Massachusetts, stroke, thrombosis, , MedCity News", "article": {"section": "Daily", "tag": "thrombosis", "published_time": "2014-08-18T12:34:44-04:00", "modified_time": "2014-09-07T23:02:18-04:00"}, "viewport": "width=device-width,initial-scale=1.0,width=device-width,user-scalable=no,minimum-scale=1.0,maximum-scale=1.0"}, "article_summary": "Exithera Pharmaceuticals, a player in the anti-thrombosis and stroke prevention drug space, appears to be in the midst of a $9 million Series B round, according to regulatory filings.\nIts major investor now \u2013 owning 65 percent of Exithera \u2013 is Israel investment group CBI, which is owned by Access Industries.\nIt has raised $3 million thus far, the filings said.\nWe\u2019re sort of grasping at straws here until Hayward calls us back \u2013 but here\u2019s a nice little precis of what the company\u2019s up to, courtesy of CBI:\nLast we heard, the Westborough, Massachusetts company raised $2 million of a $4 million Series A round in August 2012; president and CEO Neil Hayward told Mass High Tech that the funding came from Access BridgeGap Ventures, the now-defunct venture arm of Access Industries."}